HLA-B∗38:02:01 predicts carbimazole/methimazole-induced agranulocytosis

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 5, 2016, Pages 555-561

  Cheung, C L ^a,b,c   Sing, C W ^a   Tang, C S M ^c   Cheng, V K F ^a   Pirmohamed, M ^d,e   Choi, C H ^f   Hung, C S ^g   Lau, E Y F ^h   Lee, K F ⁱ   Mak, M W H ⁱ   Leung, J Y Y ^j   Wong, T W ^j   Ho, A Y Y ^k   Chan, K W ^l   Hung, V H F ^l   Tam, V ^m   Siu, S C ⁿ   Pang, H K ^h   Wat, W Z M ^h   Lee, H H Y ^h   Chung, C T ^h   Hue, R S M ^h   Sham, P C ^c   Cheung, B M Y ^b,c   Wong, I C K ^a,b,o   Tan, K C B ^c   Kung, A W C ^c   more..

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^f QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^g UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^h PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

ⁱ KWONG WAH HOSPITAL   (Hong Kong)

^j Ruttonjee and Tang Shiu Kin Hospitals   (Hong Kong)

^k TUEN MUN HOSPITAL   (Hong Kong)

^l PRINCESS MARGARET HOSPITAL   (Hong Kong)

^m Caritas Medical Centre Hong Kong   (Hong Kong)

ⁿ TUNG WAH EASTERN HOSPITAL   (Hong Kong)

^o UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; HLA B ANTIGEN; THIAMAZOLE; ANTITHYROID AGENT; PROPYLTHIOURACIL;

AGRANULOCYTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HLA TYPING; HUMAN; NEUTROPENIA; PHARMACOGENOMICS; PREDICTIVE VALUE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; CHEMICALLY INDUCED; FEMALE; GENETICS; GENOME-WIDE ASSOCIATION STUDY;

AGRANULOCYTOSIS; ANTITHYROID AGENTS; CARBIMAZOLE; CASE-CONTROL STUDIES; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HLA-B ANTIGENS; HUMANS; LINKAGE DISEQUILIBRIUM; METHIMAZOLE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROPYLTHIOURACIL;

EID: 84954135540     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.309     Document Type: Article

References (30)

1. Hollowell J.G., et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 87 489-499 (2002).
2. Pillai N.E., et al. Predicting HLA alleles from high-resolution SNP data in three Southeast Asian populations. Hum. Mol. Genet. 23, 4443-4451 (2014).
3. Garmendia Madariaga A., Santos Palacios S., Guill-en-Grima F., & Galofr-e J.C. The incidence and prevalence of thyroid dysfunction in Europe: a meta-Analysis. J. Clin. Endocrinol. Metab. 99, 923-931 (2014).
4. Cooper D.S. Antithyroid drugs. N. Engl. J. Med. 352, 905-917 (2005).
5. Chung W.H., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
6. Mallal S., et al. Association between presence of HLA-B5701, HLADR7, and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
7. Chen P., et al. Carbamazepine-induced toxic effects and HLA-B1502 screening in Taiwan. N. Engl. J. Med. 364, 1126-1133 (2011).
8. Mallal S., et al. HLA-B5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008).
9. Leckband S.G., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin. Pharmacol. Ther. 94, 324-328 (2013).
10. Carr D.F., et al. SLCO1B1 genetic variant associated with statininduced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin. Pharmacol. Ther. 94, 695-701 (2013).
11. Chen P.L., et al. Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genomewide association study. Nat. Commun. 6, 7633 (2015).
12. Hung S.I., et al. HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA 102, 4134-4139 (2005).
13. Valevski A., et al. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur. J. Immunogenet. 25, 11-13 (1998).
14. Douer D., & Eisenstein Z. Methimazole-induced agranulocytosis: growth inhibition of myeloid progenitor cells by the patient?s serum. Eur. J. Haematol. 40, 91-94 (1988).
15. Gauderman W., & Morrison J. QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies. http://citeseerx.ist.psu.edu/showciting?cid519005572 (2006).
16. Minamitani K., et al. A report of three girls with antithyroid druginduced agranulocytosis; retrospective analysis of 18 cases aged 15 years or younger reported between 1995 and 2009. Clin. Pediatr. Endocrinol. 20, 39-46 (2011).
17. Kobayashi S., et al. Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment. Thyroid 24, 796-801 (2014).
18. Wei C.Y., Lee M.T., & Chen Y.T. Pharmacogenomics of adverse drug reactions: implementing personalized medicine. Hum. Mol. Genet. 21 R58-R65 (2012).
19. Nakamura H., Miyauchi A., Miyawaki N., & Imagawa J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J. Clin. Endocrinol. Metab. 98, 4776-4783 (2013).
20. Emiliano A.B., Governale L., Parks M., & Cooper D.S. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J. Clin. Endocrinol. Metab. 95, 2227-2233 (2010).
21. Gonzalez-Galarza F.F., et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 43 Database issue), D784-D788 (2015).
22. McCormack M., et al. HLA-A3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134-1143 (2011).
23. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced cytopenia. Int. J. Clin. Pharmacol. Ther. Toxicol. 29, 75-81 (1991).
24. Kung A.W., et al. Association of JAG1 with bone mineral density and osteoporotic fractures: a genome-wide association study and follow-up replication studies. Am. J. Hum. Genet. 86, 229-239 (2010).
25. Cheung C.L., et al. Genome-wide association study identifies a susceptibility locus for thyrotoxic periodic paralysis at 17q24.3. Nat. Genet. 44, 1026-1029 (2012).
26. Dettling M., Cascorbi I., Opgen-Rhein C., & Schaub R. Clozapineinduced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J. 7, 325-332 (2007).
27. Delaneau O., & Marchini J. Integrating sequence and array data to create an improved 1000 genomes project haplotype reference panel. Nat. Commun. 5, 3934 (2014).
28. Howie B.N., Donnelly P., & Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009). 5, e1000529
29. Marchini J., Howie B., Myers S., McVean G., & Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906-913 (2007).
30. Okada Y., et al. Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. Hum. Mol. Genet. 23, 6916-6926 (2014).